Cedar Brook Financial Partners’s Gilead Sciences GILD Stock Holding History

Cedar Brook Financial Partners’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3,668	Closed	-$218K	–	366
2022 Q1	$218K	Buy	3,668 +256	+8%	+$16.4K	0.06%	344
2021 Q4	$248K	Buy	3,412 +438	+15%	+$30.2K	0.06%	320
2021 Q3	$208K	Buy	2,974 +29	+1%	+$2.04K	0.06%	325
2021 Q2	$203K	Buy	+2,945	New	+$197K	0.06%	355
2020 Q4	–	Sell	-3,500	Closed	-$221K	–	329
2020 Q3	$221K	Sell	3,500 -524	-13%	-$36.3K	0.09%	255
2020 Q2	$310K	Sell	4,024 -182	-4%	-$13.9K	0.14%	185
2020 Q1	$314K	Buy	+4,206	New	+$291K	0.17%	164
2019 Q4	–	Sell	-4,263	Closed	-$270K	–	305
2019 Q3	$270K	Buy	4,263 +246	+6%	+$16.1K	0.12%	220
2019 Q2	$271K	Buy	4,017 +86	+2%	+$5.66K	0.13%	223
2019 Q1	$256K	Buy	+3,931	New	+$261K	0.12%	221

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cedar Brook Financial Partners's GILD Position: Q2 2022 in Review

Cedar Brook Financial Partners sold out of Gilead Sciences (GILD) in Q2 2022, closing a stake of 3,668 shares — an estimated $218K sold.

Cedar Brook Financial Partners first reported a position in GILD in Q1 2019 and held it in 10 quarters. The position peaked at $314K in Q1 2020. 1,603 funds tracked by Wall St. Rank hold GILD as of Q2 2022.

Cedar Brook Financial Partners reported no remaining Gilead Sciences position as of Q2 2022 after selling out during the quarter.
Cedar Brook Financial Partners sold 3,668 Gilead Sciences shares in Q2 2022, an estimated $218K.
Cedar Brook Financial Partners first reported a position in Gilead Sciences in Q1 2019 and held it in 10 quarters.
Cedar Brook Financial Partners's Gilead Sciences position peaked at $314K in Q1 2020.
1,603 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2022.

Based on Cedar Brook Financial Partners's 13F filing for Q2 2022, filed 12 Aug 2022.